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Abstract
Background: Rift Valley fever (RVF) is a mosquito-borne viral zoonosis caused by a phlebovirus and transmitted by Aedes
mosquitoes. Humans can also be infected through direct contact with blood (aerosols) or tissues (placenta, stillborn) of
infected animals. Although severe clinical cases can be observed, infection with RVF virus (RVFV) in humans is, in most cases,
asymptomatic or causes a febrile illness without serious symptoms. In small ruminants RVFV mainly causes abortion and
neonatal death. The distribution of RVFV has been well documented in many African countries, particularly in the north
(Egypt, Sudan), east (Kenya, Tanzania, Somalia), west (Senegal, Mauritania) and south (South Africa), but also in the Indian
Ocean (Madagascar, Mayotte) and the Arabian Peninsula. In contrast, the prevalence of RVFV has rarely been investigated in
central African countries.
Methodology/Principal Findings: We therefore conducted a large serological survey of rural populations in Gabon,
involving 4,323 individuals from 212 randomly selected villages (10.3% of all Gabonese villages). RVFV-specific IgG was
found in a total of 145 individuals (3.3%) suggesting the wide circulation of Rift Valley fever virus in Gabon. The
seroprevalence was significantly higher in the lakes region than in forest and savannas zones, with respective rates of 8.3%,
2.9% and 2.2%. In the lakes region, RVFV-specific IgG was significantly more prevalent in males than in females (respectively
12.8% and 3.8%) and the seroprevalence increased gradually with age in males but not in females.
Conclusions/Significance: Although RVFV was suggested to circulate at a relatively high level in Gabon, no outbreaks or
even isolated cases have been documented in the country. The higher prevalence in the lakes region is likely to be driven by
specific ecologic conditions favorable to certain mosquito vector species. Males may be more at risk of infection than
females because they spend more time farming and hunting outside the villages, where they may be more exposed to
mosquito bites and infected animals. Further investigations are needed to determine the putative sylvan cycle of RVFV,
including the mosquito species and the reservoir role of wild animals in the viral maintenance cycle.
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Introduction
Rift Valley fever virus (RVFV) is a mosquito-borne RNA virus
belonging to the Phlebovirus genus of the Bunyaviridae family. RVFV
infects both humans and livestock [1]. Although severe clinical
cases can be observed, infection with RVF virus (RVFV) in
humans is, in most cases, asymptomatic or causes a febrile illness
without serious symptoms. Some patients may develop serious
complications, including meningoencephalitis (about 1%), hemor-
rhagic disorders (1%) and ocular disorders (retinitis and uveitis in
12% and about 30% respectively in Saudi Arabia) [2,3,4,5]. The
case fatality rate varied widely between different epidemics but
ranged between 1% to 13%. RVFV induces abortion and stillbirth
in small domestic ruminants, and has a major socio-economic
impact in African countries [6,7]. RVFV is transmitted by Aedes
mosquitoes, but humans can also be infected through direct
contact with blood (aerosols) or tissues (placenta, stillborn) of
infected animals [8,9].
RVFV was first isolated in Kenya in 1930 [10] and is now
known to be widespread in many African countries, especially in
non-forested regions. Until the 1970s, RVF was mainly reported in
southern and eastern Africa (mainly Kenya), where it was
considered as an animal disease, despite sporadic human cases
[11]. After the 1970s, explosive outbreaks occurred in human
populations throughout Africa, and principally in Egypt (1977–78,
1997–98) [2,12,13], Senegal and Mauritania (1987–1988)
[14,15,16], Kenya, Somalia and Tanzania, (1997–1998, 2006–
2007) [17,18], Chad (2004) [19], Sudan (2008) [20] and South
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[22], Mayotte and Madagascar (2007–2008) [23,24,25]. In east
Africa, RVF outbreaks coincided with heavy rainfall and local
flooding, which can lead to expansion of vector populations
[26,27]. RVFV has been detected in many wild animal species
(ungulates in Kenya, bats in Guinea, small vertebrates in Senegal
and South Africa), but it is not known whether they serve to
maintain the virus in the ecosystem during inter-epidemic periods,
or whether they contribute to amplifying outbreaks [28,29,30,31].
Although the RVFV cycle in savannas regions is now better
understood, possible sylvan cycles in forested regions have not
been explored [32].
In forested central Africa countries, no RVF outbreaks have
been described, although RVFV-specific antibodies have been
detected in wild animals and humans living in forested areas of
Central African Republic (CAR) [28,29,30,33,34,35,36] and
RVFV has been isolated from humans and wild mosquitoes
(Aedimorphus and Neolaniconion) in the same regions [37,38]. In
Gabon, one of the most densely forested countries of central
Africa, RVFV-specific antibodies were episodically detected in
humans [35] but no systematic investigation has been conducted.
We therefore undertook a large serological survey of RVFV in
Gabon, focusing on human rural populations.
Materials and Methods
Studied population
Gabon is divided into nine provinces. Three-quarters of this
country surface is covered by forest. Discontinuous areas of
savannas are also found, mainly in the south and south-east of
Gabon. In total, we collected 4323 serum samples from 212
villages (Figure 1), representing 10.7% of all villages in Gabon. No
samples were collected in towns or cities. The required sampling
population was calculated on the basis of on an estimated RVFV
seroprevalence of 5%, and the villages were randomly selected
(drawn lots, using a manual method) in the nine provinces. In each
village, volunteers were interviewed and sampled. The survey was
divided into nine time periods, corresponding to the survey of each
province. We visited Estuaire province in July 2005, Moyen
Ogooue ´ in January 2006, Woleu-Ntem in April 2006, Ngounie ´i n
June 2006, Nyanga in January 2007, Haut-Ogooue ´ in April 2007,
Ogooue ´ Ivindo in June 2007, Ogooue ´ Lolo in September 2007
and Ogooue ´ Maritime in May 2008. The villages were classified as
located in forests, savannas, or lakes zones (or Lakeland) based on
reference maps of Gabon. Forest regions were defined as dense
and continuous forest, savannas as steppes or forest gallery, and
the lakes zone as forested swamps, lagoons and lakes. In Gabon,
the most humid region is the lakes zone with an annual rainfall
about 2,000 mm and a tropical transitional humid climate.
Data and blood collection
The following data were collected for each participant, using a
standard questionnaire: demographics (age, sex, marital status),
socio-environmental conditions (main occupation, contact with the
forest, contact with animals, eating habits) and health (physical
examination, last disease and symptoms). CIRMF (Centre
International de Recherches Me ´dicales de Franceville) has
approved this study and the research. Informed consent was
written and was obtained from all participants to this survey. A
special authorization was delivered by Le Secre ´taire Ge ´ne ´ral du
Ministe `re de la Sante ´ Publique, lettre 00093/MSP/SG/SGAQM
du 15/03/2006. Blood samples were collected directly in 7-ml
EDTA Vacutainer tubes. Serum was separated each evening by
centrifugation (2000 g), stored at 220uC in cryovials (VWR,
Prolabo, France) and transported to CIRMF (Centre de
Recherches Me ´dicales de Franceville) for laboratory analysis.
Serum analysis
The sera were tested with the RVFV sandwich enzyme-linked
immunoassay (ELISA) developed and extensively validated by the
National Institute for Communicable Diseases, Sandringham,
South Africa [39]. The test uses RFVF antigen obtained from the
whole virus to detect anti-RVFV IgG antibodies in human
samples. Briefly, ELISA plates (Maxisorp, Nunc, Denmark) were
coated with mouse anti-RVFV capture antibodies diluted
1:10 000 in PBS overnight at +4uC. RVFV antigen diluted
1:500 in 2% skimmed milk in PBS was then added to the wells. A
mock antigen diluted in the same conditions was used as a control.
The test and control sera were diluted 1:400. Four high positive
controls, two low positive controls and two negative controls were
used for each plate. The specific activity of each serum (net optical
density - OD) was measured by subtracting the OD of the sample
and control wells. The mean net OD was calculated for the high
positive control serum and the reactivity of each serum was
calculated as percentage positivity (PP) of the high positive control
serum, as follows:
PP serum=100* net OD serum/mean net OD high positive
control. Sera with PP values$18 were considered positive and
those with values of 17 or below were considered negative. This
ELISA method has been validated against a serum neutralisation
test [39].
Statistical analysis
Statistical analysis was used to analyze the distribution of
RVFV-specific IgG positive samples among the sampled popula-
tion, and to determine risk factors and association between factors.
We used comparisons of means or frequencies across the two
groups (cases and non-cases) with Chi-Square test, T test, or non-
parametric tests by MC simulation, and we analyze the association
between RVFV-IgG and age with linear regression. We calculate
odds ratios (OR) for exposure factors, and adjusted OR with
possible confounding factors (age, gender, ecosystem), with
Author Summary
Rift Valley fever (RVF) is a disease transmitted by a
mosquito bite (Aedes). Humans can also be infected
through direct contact with blood (aerosols) or tissues
(placenta, stillborn) of infected animals. Although severe
clinical cases can be observed, infection with RVF virus
(RVFV) in humans in most cases causes a febrile illness
without serious symptoms. In small ruminants RVFV mainly
causes abortion and neonatal death. RVFV distribution has
been poorly investigated in Central Africa. We conducted a
large scale serological survey of RVF antibodies in rural
populations in Gabon, involving 4,323 individuals from 212
randomly selected villages. The results showed an overall
RVFV prevalence of 3.3%, with values of 2.9% in the
forested zones, 2.2% in savannas and 8.3% in the lakes
region. These findings strongly suggest for the first time
the wide circulation of Rift valley fever virus in Gabon and
the possible existence of a sylvan cycle of RVF virus in this
country. The serological higher prevalence in the lake
region suggests that this region is likely to have particular
ecological conditions, especially mosquito vector species,
favoring the circulation of this virus. In Gabon, human
cases of RVF may occur but are either misdiagnosed or not
reported.
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tivariate models stratified by ecosystem were constructed (logistic
regression), which included univariate analysis of risk factors with
significance level of #0.10, and the backwards stepwise elimina-
tion procedure was applied. Odds Ratios (OR) and exact 95%
confidence intervals (CI) were used to access the association
between risk factors and RVFV IgG seroprevalence. Statistical
significance at 0.05 risk was used in tests and for confidence
intervals (CI). Finally, we used 0.005 for risk factors analysis to take
in account a Bonferroni correction for multitesting. We used
STATA 10.0 software (College Station, Texas USA), Epi Info
software (6.04, Epiconcept), SavGIS software (9.05, IRD).
Results
Characteristics of the population and overall RVFV
specific IgG prevalence
A total of 4323 villagers were interviewed with a mean age of
46.9 years (range 15–90 years) (Table 1). Females comprised
52.9% and males 47.1% of the total. Seventy six percent of the
study participants lived in forested areas, 13% in savanna, and
11% in the lake region. The overall RVFV-specific IgG
seroprevalence was 3.3%, with 4.3% in males and 2.5% in
females. Seroprevalence was highest in the lake area (8.3%),
followed by the savanna (2.9%), and the forest (2.2%). Hunters
had the highest seroprevalence of those tested at 4.4%, followed by
3.5% in farmers and 2.4% for other professions combined. In the
212 surveyed villages (Figure 1), the RVFV IgG seroprevalence
rates varied from 0 to 38%. Three levels of seroprevalence rates
were defined: low (0–4%), intermediate (5–15%) and high (.15%)
(Figure 2A, 2B, 2C). So, 155 (73%) villages were at low level, 51
(24%) at intermediate level and six (3%) at high level of RVFV
IgG seroprevalence (Table 2). In forest and savanna areas,
respectively 75% and 87% of the villages were at low level and
respectively 24% and 13% at intermediate level. In the lakes
region, the RVFV IgG prevalence was .5% in 14 villages (56%)
Figure 1. Location of the 212 villages (circles) sampled in the three main Gabonese ecosystems: forest (green), savannas (yellow)
and lakes (brown).
doi:10.1371/journal.pntd.0000763.g001
Table 1. Sociodemographic characteristics and RVFV IgG







All 4323 145 3.3
Sex Male 2038 88 4.3
Female 2285 57 2.5
Age [15–33[ 867 16 1.8
[33–44[ 851 30 3.5
[44–54[ 896 27 3
[54–61[ 959 35 3.6
[61–90] 750 35 4.7
Occupation Hunters 435 19 4.4
Others 867 21 2.4
Farmers 3021 105 3.5
Ecosystem Forest 3312 95 2.9
Savanna 551 12 2.2
Lake 460 38 8.3
doi:10.1371/journal.pntd.0000763.t001
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doi:10.1371/journal.pntd.0000763.g002
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Elyse and Bordeaux) had high rates, respectively 27% (4/15) and
38% (5/13).
Analysis of risk factors
Only the age, the gender and the ecosystem allowed rejecting
the NULL hypothesis (of no significant relationship with RVFV-
specific IgG prevalence). In particular, no statistical significance
was found according to the activity of the villagers. We calculate
ORs with confidence intervals, and p-value of the Chi-Square in a
case-exposure test. Results are shown in Table 3.
Age factor: the age mean in the RVFV IgG positive group was
50.7 and 46.8 in the negative one (p,0.001). We class the age in 5
categories, near quintiles ([15–33[, [33–44[, [44–54[, [54–61[,
[61–90]) for ORs and risk analysis. A significant (p=0.00002)
linear increase of RVFV IgG prevalence was noted between
ordered age groups (Figure 3), even with a Bayesian adjustment
(EBE) to reduce the variability difference between the groups.
Gender factor: gender shows a strong relationship RVFV
specific IgG. The prevalence was higher in the male group (4.32%,
OR=1.75, [1.25, 2.46], Chi-Square=11.05, p=0.00089), than in
the female group (2.50%, OR=0.57, [0.41, 0.80], Chi-
Square=11.05, p=0.00089). In order to highlight a possible
confounding factor, adjusted OR with ecosystem or age were
performed. These ORs did not show a significant difference (1.68
and 1.59 for the males and 0.59 and 0.62 for the females), showing
that age distribution in positive samples has same distribution
whatever the gender.
Ecosystem factor: ecosystem shows a strong OR difference
(Table 3), with high risk in the lake ecosystem (OR=3.2). Adjusted
ORs with age and/or gender don’t show any confounding factors
(Table 4).
Study of risk factors per ecosystem
In the forest and savanna areas, no significant relationship with
RVFV-specific IgG prevalence and possible risk factors were
found, except the activity (to be hunter, in these two ecosystems).
The results are shown in Table 5. However, in the lake ecosystem,
gender was a very high risk factor (OR=4.44). Similarly than in
the global population, the RVFV IgG prevalence rate increased
with age. No other risk factor was highlighted.
Logistic regression analysis
Finally, multivariate analyses were performed by ecosystem.
Only in the lakes region, gender and age remained significantly
associated with a positive RVFV- IgG, with respectively adjusted
OR=3.85 [1.75–8.33], p=0.001 and adjusted OR=1.03 [1.01–
1.059, p=0.01 (Table 6).
Discussion
In this large serological survey, covering 10.7% of all Gabonese
villages, we found an overall RVFV-specific IgG prevalence rate of
3.3%. This is surprisingly high for a country in which no RVFV
outbreaks have ever been reported. As in Central Africa Republic,
Table 2. RVFV IgG prevalence in the 212 villages of Gabon,
classified by ecosystem.
Region and number of villages (% per region)
IgG prevalence (%) Lakes Forests Savannas Total
0–4 11 (44) 118 (75) 26 (87) 155 (73)
5–14 8 (32) 39 (24) 4 (13) 51 (24)
.15 6 (24) 0 0 6 (3)
Total 25 (100) 157 (100) 30 (100) 212 (100)
doi:10.1371/journal.pntd.0000763.t002
Table 3. RVFV-IgG prevalence risk analysis for age, gender, ecosystem, occupation.
Mean or frequency in
positive samples
Mean or frequency in




Male 60.69% 46.74% 0.00032 1.75 [1.25,2.46] 0.00089
Female 39.31% 53.28% 0.00035 0.57 [0.41,0.80] 0.00089
Age 50.68% 46.85% 0.0005 0.0006
[15–33[ 11.03% 20.31% 0.0024 0.49 [0.29, 0.83] 0.0058
[33–44[ 20.68% 19.69% 0.37 1.04 [0.69 , 1.57] 0.75
[44–54[ 18.62% 20.91% 0.24 0.87 [0.57 , 1.34] 0.52
[54–61[ 24.13% 22.20% 0.28 1.11 [0.76 , 1.64] 0.56
[61–90] 25.52% 17.18% 0.0029 1.69 [1.16 , 2.48] 0.0082
Ecosystem
Forest 65.5% 77.0% 0.0004 0.57 [0.40, 0.80] 0.0013
Lakes 26.2% 10.1% ,0.00001 3.20 [2.18 , 4.70] ,0.00001
Savanna 8.3% 12.9% 0.05 0.60 [0.33 , 1.09] 0.10
Occupation
Farmer 72.41% 69.73% 0.23 1.12 [0.78 , 1.59] 0.50
Hunter 13.10% 9.97% 0.10 1.36 [0.83 , 2.23] 0.21
Others 14.48% 20.26% 0.04 0.67 [0.42 , 1.07] 0.09
Confident Intervals of Odd-Ratios correspond to 5% risk.
doi:10.1371/journal.pntd.0000763.t003
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serological surveys of people living in forested areas, in 1979–82,
1984–85 and 1994–97, showed RVFV-specific IgG prevalence
rates ranging from 1.2% to 6.9% [33,35,36].
In countries with documented Rift Valley fever epidemics, the
RVFV-specific IgG prevalence rates, measured in outbreak areas,
were as high as 32% in Kenya in 1997 [17], 22.3% in Senegal in
1989 [16] and 24.4% in Mauritania in 1998 [40]. During
interepidemic periods in Kenya, the RVFV IgG prevalence rates
ranged from 1% to 19% [9,41]. In Tanzania, a 2004 study showed
a RVFV-specific IgG prevalence rate of 4% [42]. Thus, these data
registered during interepidemic periods from epidemic countries
are similar to those found in Gabon.
This result strongly suggests widespread circulation of Rift valley
fever virus in Gabon even if the epidemiological cycle and the
modalities of this circulation remain unknown. Classically, the
RVFV cycle involves domestic animals (livestock) as viral
amplifying hosts before transmission to humans, as has been
Figure 3. RVFV specific IgG seroprevalence according to the age class in Gabonese population.
doi:10.1371/journal.pntd.0000763.g003
Table 4. Analysis of RVFV-IgG seroprevalence in the three ecosystems of Gabon with possible confounding factors: gender, age
and a combination of age and gender.
OR (Forest) OR (Lakes) OR (Savanna)
All 0.57 [0.40 , 0.80] 3.20 [2.18 , 4.70] 0.60 [0.33 , 1.09]
Age
[15–33] 0.45 [0.17,1.25] 3.60 [1.23,10.58] 0.60 [0.08 , 4.61]
[33–44] 0.90 [0.39,2.03] 1.43 [0.49, 4.19] 0.89 [0.30 , 2.59]
[44–54] 1.13 [0.45,2.84] 1.66 [0.56, 4.92] 0.45 [0.11 ,1.93]
[54–61] 0.49 [0.24,0.99] 4.27 [1.86, 9.79] 0.87 [0.33 , 2.28]
[61–90] 0.34 [0.17,0.66] 5.22 [2.64,10.30] -
Adjusted Age 0.55 [0.39, 0.79] 3.37 [2.25 , 5.04] 0.75 [0.41 , 1.39]
Gender
Female 0.96 [0.52,1.76] 1.69 [0.82 , 3.49] 0.60 [0.24 , 1.52]
Male 0.41 [0.27,0.64] 4.44 [2.78, 7.09] 0.62 [0.28 , 1.36]
Adjusted Gender 0.55 [0.38, 0.78] 3.34 [2.25 , 4.95] 0.61, [0.34 , 1.11]
Adjusted Age and Gender 0.53 [0.37, 0.76] 3.83 [2.52 , 5.81] 0.84, [0.45 , 1.55]
doi:10.1371/journal.pntd.0000763.t004
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herds are rare (except around major cities) and, in the rural areas
where our investigations were carried out, few domestic animals
such as cows, sheep and goats were found. Thus, in Gabon, the
RVFV cycle may involve wild rather than domestic animals. This
is supported by the isolation of RVFV from a specific forest
mosquito, Aedes (Neomelaniconion) gr. Palpalis [38], in the Central
African Republic and the detection of IgG in pygmies living in
regions of this country where domestic animals are virtually absent
[34].
One possible reason for the lack of reported RVF outbreaks or
even isolated cases in Gabon is that cases of RVF might be
attributed to malaria. Alternatively, less virulent strains may be
circulating in Gabon. Although cross serological reactions with
antibodies against unknown phleboviruses cannot be definitively
ruled out, serological cross reactions against known phleboviruses
are unlikely as the commercial ELISA method used in this survey
has been extensively validated against a serum neutralisation test
and was shown to be highly sensitive and specific for routine
testing of human samples [39].
As RVFV transmission may vary with the local environment
and vector distribution [41], we analyzed the results according to
the principal ecosystems found in Gabon. We found a significantly
Table 5. Odd ratios and adjusted odds ratios with possible confounding factors for the presence of RVFV antibodies according to
potential risk factors, stratified by ecosystem, in Gabon.
Region Variables IgG (%) OR Adjusted OR (Age) Adjusted OR (Gender)
Forest Gender Female 2.47% 0.74 [0.49 , 1.12] 0.77[0.51, 1.16] -
Male 3.31% 1.34 [0.89 , 2.02] 1.30 [0.86 , 1.96] -
Age [15–33[ 1.48% 0.45 [0.23 , 0.87] - 0.46 [0.24 , 0.89]
[33–44[ 3.44% 1.24 [0.76 , 2.01] - 1.25 [0.77 , 2.03]
[44–54[ 3.10% 1.11 [0.68 , 1.81] - 1.13 [0.69 , 1.85]
[54–61[ 2.96% 1.05 [0.65 , 1.70] - 1.05 [0.65 , 1.71]
[61–90] 3.47% 1.30 [0.79 , 2.15] - 1.28 [0.78 , 2.12]
Occupation Farmer 2.92% 1.06 [0.68 , 1.65] 0.95 [0.61 , 1.49] 1.23 [0.75 , 2.01]
Hunter 3.64% 1.31 [0.71 , 2.43] 1.97 [1.03 , 3.76] 1.13 [0.59 , 2.18]
Others 2.33% 0.78 [0.45 , 1.34] 1.02 [0.59 , 1.77] 0.72 [0.41 , 1.25]
Lakes Gender Female 3.83% 0.27 [0.13 , 0.59] 0.30 [0.13 , 0.71] -
Male 12.89% 3.66 [1.69 , 7.93] 3.29 [1.42 , 7.65] -
Age [15–33[ 4.85% 0.52 [0.20 , 1.36] - 0.69 [0.25 , 1.92]
[33–44[ 4.76% 0.49 [0.17 , 1.41] - 0.43[0.151, 1.26]
[44–54[ 4.54% 0.48 [0.17 , 1.39] - 0.64 [0.21 , 1.93]
[54–61[ 11.43% 1.58 [0.69 , 3.60] - 1.41 [0.60 , 3.30]
[61–90] 14.78% 2.62 [1.33 , 5.16] - 2.97 [1.48 , 5.94]
Occupation Farmer 9.86% 1.99 [0.89 , 4.44] 1.37 [0.58 , 3.22] 2.56 [1.14 , 5.77]
Hunter 8.10% 1.01 [0.30 , 3.47] 1.99 [0.53 , 7.53] 0.58 [0.17 , 2.02]
Others 4.20% 0.41 [0.16 , 1.08] 0.98 [0.33 , 2.90] 0.42 [0.16 , 1.11]
Savanna Gender Female 1.62% 0.56 [0.17 , 1.78] 0.73 [0.22 , 2.44] -
Male 2.89% 1.79 [0.56 , 5.72] 1.37 [0.41 , 4.61] -
Age [15–33[ 1.12% 0.50 [0.06 , 3.91] - 1.32[0.15, 11.38]
[33–44[ 3.12% 1.71 [0.51 , 5.77] - 1.75 [0.51 , 5.96]
[44–54[ 1.54% 0.64 [0.14 , 2.95] - 0.66 [0.14 , 3.08]
[54–61[ 3.42% 1.90 [0.59 , 6.07] - 1.78 [0.55 , 5.70]
[61–90] 0% 0 - -
Occupation Farmer 1.90% 0.60 [0.18 , 2.01] 0.45 [0.11, 1.88] 0.59 [0.13 , 2.70]
Hunter 5.80% 3.75 [1.10, 12.82] 4.59 [1.06, 19.79] 3.64[0.80, 16.72]
Others 0% 0 - -
doi:10.1371/journal.pntd.0000763.t005
Table 6. Adjusted seroprevalence and odds ratios in logistic
regression for the presence of RVFV antibodies according to
potential risk factors stratified by ecosystem, in Gabon.
Ecosystem Risk factor Adjusted OR 95%CI P value
Forest Gender 1.31 0.86–1.97 0.2
Age 1.10 0.99–1.03 0.07
Savanna Gender 1.82 0.56–5.88 0.32
Age 1.00 0.96–1.05 0.97
Lakes Gender 3.85 1.75–8.33 0.001
Age 1.03 1.01–1.05 0.01
doi:10.1371/journal.pntd.0000763.t006
Rift Valley Fever Seroprevalence in Gabon
www.plosntds.org 7 July 2010 | Volume 4 | Issue 7 | e763higher RVFV IgG prevalence in the lakes region (8.2%) than in
forest (2.9%) and savanna (2.1%) areas.
The lakes region is the most humid region of Gabon and is
mainly composed of swamps and forested lagoons. This ecological
situation, with omnipresent surface waters, could favor various
mosquito species (or higher densities than elsewhere). A relation-
ship has already been found between RVFV circulation and water
resources in Kenya [41], Egypt [42], Senegal [43] and Saudi
Arabia [44]. However, in Gabon, further investigation is needed to
identify the mosquito species involved in RVFV transmission. In
this ecosystem, the RVFV IgG prevalence was significantly higher
(OR=4.44, Table 4) in males (12.8%) than females (2.8%), and
increased regularly with age (Table 6, Figure 3).
In the lakes region, males spend a large part of the day outside
their villages, engaged in agriculture or hunting (or fishing). In
contrast, females spend less time in agricultural activities and do
not hunt; they remain indoors the rest of the time, cooking and
taking care of infants. Thus, the higher RVFV IgG prevalence in
males may be due to higher exposure to RVFV vectors or to
infected animals. A similar gender difference was found in Kenya
in 2006, where males had an RVFV IgG prevalence rate more
than three times higher than females [41]. The reasons of the
RVFV IgG seroprevalence increase according to age are
unknown. This could be compatible with a continuous exposure
of Gabonese populations to RVFV but also to a higher rate of
exposition to mosquito vector bites infected with RVFV of the
older age groups.
In conclusion, this first large serological survey of RVFV in
central Africa strongly suggests that the virus circulates widely in
Gabon, despite the lack of reported outbreaks. The overall high
RVFV seroprevalence observed in Gabon suggests that human
cases of RVF may occur but are either misdiagnosed or not
reported. However, cross serological reactions with unknown
phleboviruses cannot be ruled out. Further investigations are
needed to isolate the Rift valley virus from human, animal or
mosquito samples, to investigate the putative sylvan cycle of
RVFV, and particularly to identify the mosquito species involved
in human transmission and the potential role of wild animals as
reservoir.
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